Graeme Fraser

3.2k total citations
57 papers, 1.6k citations indexed

About

Graeme Fraser is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Graeme Fraser has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 28 papers in Pathology and Forensic Medicine and 12 papers in Oncology. Recurrent topics in Graeme Fraser's work include Chronic Lymphocytic Leukemia Research (33 papers), Lymphoma Diagnosis and Treatment (27 papers) and Advanced Breast Cancer Therapies (7 papers). Graeme Fraser is often cited by papers focused on Chronic Lymphocytic Leukemia Research (33 papers), Lymphoma Diagnosis and Treatment (27 papers) and Advanced Breast Cancer Therapies (7 papers). Graeme Fraser collaborates with scholars based in Canada, United States and United Kingdom. Graeme Fraser's co-authors include Wendy Lim, Donald M. Arnold, Ralph M. Meyer, Richard J. Cook, Christopher Hillis, Darryl P. Leong, John G. Kelton, Christopher Sigouin, Mark Crowther and Francesco Dentali and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Graeme Fraser

52 papers receiving 1.5k citations

Peers

Countries citing papers authored by Graeme Fraser

Since Specialization

Citations

This map shows the geographic impact of Graeme Fraser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graeme Fraser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graeme Fraser more than expected).

Fields of papers citing papers by Graeme Fraser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graeme Fraser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graeme Fraser. The network helps show where Graeme Fraser may publish in the future.

Co-authorship network of co-authors of Graeme Fraser

This figure shows the co-authorship network connecting the top 25 collaborators of Graeme Fraser. A scholar is included among the top collaborators of Graeme Fraser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graeme Fraser. Graeme Fraser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis 2025 ·eJHaem ·(unknown), Dong An, Gregory R. Pond, Tobias Berg, (unknown), (unknown), (unknown), Graeme Fraser, Ronan Foley, (unknown)	0
2	Lentivirus‐mediated gene therapy for Fabry disease: 5‐year End‐of‐Study results from the Canadian FACTs trial 2025 ·Clinical and Translational Medicine ·Anzalee Khan, Dwayne L. Barber, William M. McKillop, C. Anthony Rupar, Christiane Auray‐Blais, Graeme Fraser, Daniel H. Fowler, Alexandra Berger, Ronan Foley, Armand Keating, Michael L. West, Jeffrey A. Medin	4
3	Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy 2024 ·BMC Cancer ·(unknown), Gregory R. Pond, (unknown), Graeme Fraser, (unknown), Mark N. Levine, (unknown), Ronan Foley	1
4	Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP 2024 ·British Journal of Haematology ·Douglas A. Stewart, John Kuruvilla, David M. Lee, (unknown), Neil Chua, (unknown), Tara Baetz, Mona Shafey, (unknown), Sue Robinson, Isabelle Fleury, Graeme Fraser, (unknown), Vishal Kukreti, (unknown), Annette E. Hay, Lois E. Shepherd, Bingshu E. Chen, Michael Crump	0
5	Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials 2023 ·Hematological Oncology ·Alessandra Tedeschi, Inhye E. Ahn, Graeme Fraser, Richard Greil, Talha Munir, Neil E. Kay, Ian W. Flinn, Shane Lee, Chadi Saifan, Jeffrey D. Kearbey, Sandipkumar Patel, Jacqueline C. Barrientos	0
6	Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation 2021 ·Current Oncology Reports ·(unknown), Christopher Hillis, Graeme Fraser, Darryl P. Leong	29
7	First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma 2020 ·Current Oncology ·Sita Bhella, (unknown), Andrew Aw, Christopher Bredeson, Matthew C. Cheung, Michael Crump, Graeme Fraser, (unknown), (unknown)	2
8	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial 2019 ·Pharmaceutical Research ·(unknown), Jan de Jong, (unknown), Paula Cramer, Fatih Demırkan, Graeme Fraser, Nancy L. Bartlett, Marie‐Sarah Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, André Goy, Siddhartha Ganguly, Mariya Salman, Angela Howes, Michelle Mahler, Giuseppe De Nicolao, Italo Poggesi	3
9	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Susan O’Brien, Peter Hillmen, Steven Coutré, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie‐Sarah Dilhuydy, Georg Heß, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, (unknown), Thorsten Graef, (unknown)	63
10	Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study 2018 ·Blood ·Richard Greil, Graeme Fraser, Brian Leber, Reinhard Marks, Giulia Quaresmini, Jan Moritz Middeke, Gianpietro Semenzato, William Schary, Michelle Boyer, Madlaina Breuleux, (unknown), Kathryn Humphrey, Paula Marlton	7
11	Canadian Evidence-Based Guideline for the First-Line Treatment of Chronic Lymphocytic Leukemia 2018 ·Current Oncology ·Carolyn Owen, Alina S. Gerrie, Versha Banerji, Sarit Assouline, Christine Chen, Katherine Robinson, (unknown), Graeme Fraser	8
12	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis 2017 ·Blood Advances ·François Caron, Darryl P. Leong, Christopher Hillis, Graeme Fraser, Deborah Siegal	82
13	IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY 2016 ·Haematologica ·Graeme Fraser, Paula Cramer, Fatih Demırkan, (unknown), Sebastian Grosicki, Ann Janssens, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, André Goy, Abraham Avigdor, (unknown), Charles E. Phelps, Michelle Mahler, Mariya Salman, Angela Howes, Michael Hallek	4
14	Accrual of Adolescents and Young Adults with Cancer to Clinical Trials 2016 ·Current Oncology ·Annette E. Hay, Charlene Rae, Graeme Fraser, Ralph M. Meyer, (unknown), Stuart Bevan, Mary L. McBride, Geoff D.E. Cuvelier, (unknown), Ronald D. Barr	18
15	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial* 2016 ·Leukemia & lymphoma ·Clemens‐Martin Wendtner, Michael Hallek, Graeme Fraser, (unknown), Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Bühler, Thomas J. Kipps, (unknown), Jennie Zhang, (unknown), Jay Mei, Asher Chanan‐Khan	15
16	Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Rena Buckstein, Graeme Fraser, Matthew C. Cheung, Vishal Kukreti, John Kuruvilla, Kevin Imrie, Eugenia Piliotis, Gregory R. Pond, (unknown), Zeina Ghorab, (unknown), (unknown), Ralph M. Meyer, K.I. Pritchard, Scott E. Walker, Mark Levine, Michael Crump	11
17	Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre 2014 ·Value in Health ·Nicole Mittmann, (unknown), Soo Jin Seung, (unknown), Matthew C. Cheung, Graeme Fraser, Shai Fine, (unknown)	2
18	Identifying the supportive care needs of adolescent and young adult survivors of cancer: a qualitative analysis and systematic literature review 2013 ·Supportive Care in Cancer ·Elena Tsangaris, Jessica L. Johnson, Rachel M. Taylor, Lorna A. Fern, Denise Bryant‐Lukosius, Ronald D. Barr, Graeme Fraser, Anne F. Klassen	79
19	Principles and Recommendations for the Provision of Healthcare in Canada to Adolescent and Young Adult–Aged Cancer Patients and Survivors 2011 ·Journal of Adolescent and Young Adult Oncology ·Conrad V. Fernandez, Graeme Fraser, Carolyn Freeman, Eva Grunfeld, Abha A. Gupta, Leslie S. Mery, Sonja De Pauw, (unknown)	90
20	Avoiding Transfusions in Children Undergoing Cardiac Surgery: A Meta-Analysis of Randomized Trials of Aprotinin 2006 ·Anesthesia & Analgesia ·Donald M. Arnold, Dean Fergusson, Anthony K.C. Chan, Richard J. Cook, Graeme Fraser, Wendy Lim, Morris A. Blajchman, (unknown)	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact